IRB Study Number 18-1385
Status Completed
Location Cleveland Clinic Main Campus
Institute Endocrinology and Metabolism Institute
Description
Validation study for the Alertgy non-invasive continuous glucose monitor (ANICGM)
This study aims to validate the glucose readings taken from the ANICGM with an approved outpatient glucose meter in patients with type 2 diabetes.
Inclusion Criteria
Type 2 diabetes on diet or on pharmacologic treatment for diabetes
Hemoglobin A1c (HbA1c) 7.5-10.0%
Age 18-75 years old
Exclusion Criteria
Patients taking prandial insulin
Fasting blood glucose by fingerstick <70 mg/dL or >250 mg/dL. Hypoglycemia <70 mg/dL will be treated according to clinic protocol.
Pregnancy
ESRD
Decompensated or acute heart failure
Medications that might cause false readings with glucose meters: acetaminophen, ascorbic acid, dopamine, maltodextrin, mannitol
